|
|
|
|
|
|
|
|
|
|
| Estimated Vaccination Coverage With Selected Vaccines Among
Adolescents Aged 13-17* Years by Age at Interview |
| --National Immunization Survey-Te=
en,
United States, 2009 |
| |
|
|
|
|
|
|
|
|
Age at Interview (years) |
|
|
|
13 |
14 |
15 |
16 |
17 |
|
2009 |
|
n =3D 3,915 |
n =3D 4,203 |
n =3D 4,162 |
n =3D 4,084 |
n =3D 3,702 |
|
n =3D 20,066 |
| Vaccines |
% (95% CI)† |
% (95% CI) |
% (95% CI) |
% (95% CI) |
% (95% CI) |
|
% (95% CI) |
| MMR§ ≥ 2 d=
oses |
91.2 (89.5-92.6) |
89.3 (87.6-90.8) |
86.9 (84.6-88.9) |
90.9 (89.2-92.4) |
87.6 (85.3-89.6) |
|
89.1 (88.3-89.9) |
| Hepatitis B ≥ 3 doses |
93.4 (92.1-94.5) |
90.6 (88.9-92.1) |
89.9 (88.0-91.5) |
90.0 (88.1-91.6) |
85.6 (83.7-87.3) |
|
89.9 (89.2-90.6) |
| Varicella |
|
| History
of varicella disease<=
font
class=3D"font12">¶ |
33.7 (31.2-36.3) |
42.0 (39.3-44.7) |
55.3 (52.4-58.1) |
62.8 (59.8-65.7) |
69.6 (66.7-72.3) |
|
52.7 (51.4-54.0) |
| ≥ 1 dose vaccine if had no
history of disease |
93.6 (92.0-94.9) |
89.8 (87.4-91.8) |
87.2 (83.8-89.9) |
80.4 (76.2-84.0) |
75.3 (70.1-79.9) |
|
87.0 (85.7-88.2) |
| ≥ 2 doses vaccine if had no
history of disease |
54.3 (50.8-57.8) |
50.2 (46.1-54.2) |
49.6 (45.2-54.1) |
44.1 (38.5-49.7) |
37.1 (31.9-42.6) |
|
48.6 (46.6-50.6) |
| History
of disease or received ≥ 2 doses varicella vaccination** |
69.7 (67.0-72.3) |
71.1 (68.5-73.5) |
77.5 (75.0-79.8) |
79.2 (76.8-81.4) |
80.9 (78.3-83.2) |
|
75.7 (74.6-76.8) |
| Td or Tdap since age=
10 years |
|
| ≥
1 dose Td or Tdap§§ |
70.5 (67.9-73.0) |
74.8 (72.4-77.1) |
78.2 (75.9-80.3) |
78.4 (75.9-80.8) |
78.5 (76.0-80.8) |
|
76.2 (75.1-77.2) |
| ≥
1 dose Tdap |
65.2 (62.5-67.8) |
63.5 (60.8-66.2) |
58.3 (55.5-61.0) |
46.8 (43.9-49.7) |
43.6 (40.7-46.5) |
|
55.6 (54.3-56.8) |
| MenACWY¶¶ ≥1 do=
se |
53.8 (51.0-56.5) |
56.1 (53.3-58.9) |
54.6 (51.8-57.4) |
54.4 (51.5-57.3) |
48.8 (45.9-51.7) |
|
53.6 (52.4-54.9) |
| HPV*** |
|
|
| ≥ 1 dose |
37.1 (33.5-40.9) |
40.6 (36.8-44.6) |
46.0 (42.1-50.0) |
49.9 (45.5-54.3) |
47.1 (43.1-51.2) |
|
44.3 (42.4-46.1) |
| ≥ 3 doses |
19.5 (16.8-22.5) |
23.2 (20.3-26.4) |
25.7 (22.6-29.0) |
33.2 (29.5-37.2) |
31.6 (27.9-35.5) |
|
26.7 (25.2-28.2) |
| |
|
|
|
|
|
|
|
|
|
|
| * Adolescents in the 2009 NIS-Teen were born during January
1991-February 1997. Vaccination coverage estimates include only adolescen=
ts
who had adequately complete provider-reported immunization records. Natio=
nal
estimates do not include adolescents living in the U.S. Virgin Islands (i=
.e.,
St. Croix, St. Thomas, St. John, and Water Island) (n=3D333). |
| †State estimate presented as point estimate (%) ± 9=
5%
confidence interval (CI). |
| §
≥2 measles, mumps, and rubella vaccine=
. |
| ¶ By
parent/guardian report or provider records. |
| ** Prior tables reported "history of disease or receive
≥1 dose varicella vaccination." We now report "history of
disease or receive ≥2 doses varicella vaccination" to follow
current Advisory Committee of Immunization Practices guidelines for adequ=
ate
protection against varicella infection. |
|
|
| §=
;§ ≥1 tetanus and diptheria toxoid vaccine (Td), tet=
anus
toxoid, reduced diptheria toxid, and acellular pertussis (Tdap), or
tetanus-unknown type vaccine. |
| ¶¶ X=
05;1
meningococcal conjugate vaccine or meningococcal-unknown type vaccine. |
| *** X=
05;1
human papillomavirus vaccine, either quadrivalent or bivalent. Percentages
reported among females only (n=3D9,621). |
|
|
|
|
|
|
|
|
|
|
|
------=_NextPart_01CB3FB7.D0446760
Content-Location: file:///C:/C45E1145/tab18_byage_files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"